Xolair 150 MG/ML autoinjectorml
Ended Awarded Last action
- Contract number
- SPE2DR26FSKE7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $5,242
Award facts
- Contract value 100% obligated
- $5,242.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $5,242.32 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/mL autoinjector. The delivery order, issued on December 2, 2025, with an ultimate completion date of December 23, 2025, carries no set-aside designation, indicating that DMS Pharmaceutical Group competed successfully in unrestricted federal procurement. This award represents a single delivery order executed under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish regional prime vendor contractors for the Department of Defense's pharmaceutical supply needs.
DMS Pharmaceutical Group has demonstrated substantial capability as a critical pharmaceutical supplier within the federal military medical supply chain, with the parent PPV-G GEN V contract—valued at $499.999 billion and extending through December 31, 2036—authorizing the company to fulfill recurring medical supply requirements for DoD healthcare facilities worldwide. The Xolair delivery represents a specialty pharmaceutical product supporting immunological treatment needs across the military healthcare system. As the sole prime contractor on this delivery order with no identified subcontractor relationships, DMS Pharmaceutical Group leverages its established performance history across multiple therapeutic categories and product lines to supply specialized biologics and medications essential to Department of Defense operations.
Quick answers
Who was awarded contract SPE2DR26FSKE7?
SPE2DR26FSKE7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 2, 2025.
How much is contract SPE2DR26FSKE7 worth?
The government has obligated $5,242 on SPE2DR26FSKE7.
Is contract SPE2DR26FSKE7 an order under another contract?
Yes. SPE2DR26FSKE7 is a delivery order under SPE2DR25D9317, an indefinite delivery contract.
Was contract SPE2DR26FSKE7 competed?
The extent of competition for SPE2DR26FSKE7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award